<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In eukaryotes, post-translational modification of <z:chebi fb="0" ids="15358">histones</z:chebi> is critical for regulation of chromatin structure and gene expression </plain></SENT>
<SENT sid="1" pm="."><plain>EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 on lysine 27 (H3K27) </plain></SENT>
<SENT sid="2" pm="."><plain>EZH2 overexpression is implicated in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and correlates with poor prognosis in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types </plain></SENT>
<SENT sid="3" pm="."><plain>Additionally, somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The Y641 residue is the most frequently mutated residue, with up to 22% of germinal centre B-cell <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> harbouring mutations at this site </plain></SENT>
<SENT sid="5" pm="."><plain>These <z:hpo ids='HP_0002665'>lymphomas</z:hpo> have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes </plain></SENT>
<SENT sid="6" pm="."><plain>However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Here we demonstrate that GSK126, a potent, highly selective, S-<z:chebi fb="0" ids="33505">adenosyl</z:chebi>-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes </plain></SENT>
<SENT sid="8" pm="."><plain>GSK126 effectively inhibits the proliferation of EZH2 mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cell lines and markedly inhibits the growth of EZH2 mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> xenografts in mice </plain></SENT>
<SENT sid="9" pm="."><plain>Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>